STOCK COMMENTS / EPS CHANGES
numbers boosted at FBR Capital Markets. Shares now seen reaching $27. Estimates also raised, as the credit turnaround is gaining momentum. Outperform rating.
estimates were raised through 2012 at FBR Capital Markets. Company had a weak quarter, but is seeing higher met coal volumes. Outperform rating and $39 price target.
estimates, target boosted at FBR Capital Markets. Shares now seen reaching $43. Company is seeing higher demand and gaining market share. Market Perform rating.
(C - Get Report)
estimates, target increased at UBS. Shares now seen reaching $5. Estimates also raised, even though numbers should tail off from a strong first quarter. Neutral rating.
Citigroup target, estimates raised at Barclays. Price target increased $1 to $6 after mixed first-quarter results. 2010 and 2011 EPS estimates lifted to 35 cents and 45 cents, respectively. Overweight rating.
target, estimates raised at Barclays. Price target increased $1 to $24. Expecting an earnings beat and raised guidance. 2010 and 2011 EPS estimates increased to $1.85 and $2.00, respectively.
estimates, target raised at Goldman Sachs. Estimates were increased through 2012. Company is seeing higher margins in North America, and international growth is around the corner. Buy rating and new $43 price target.
numbers raised at FBR Capital Markets. Shares now seen reaching $40, according to FBR Capital Markets. Estimates also increased, as checks suggest the company is seeing higher sales trends. Outperform rating.
numbers boosted at Barclays. IBM 2010 and 2011 EPS estimates raised to $11.22 and $12.40, respectively, as company's first quarter was in line with expectations. Maintain Equal Weight rating and $145 price target.
IBM estimates boosted at Goldman Sachs through 2012. Company is seeing higher sales, but currency trends are adding to costs. Neutral rating and $140 price target.
numbers cut at Barclays. 2010 and 2011 EPS estimates sunk to $4.49 and $4.29, respectively. 35-cent negative impact to EPS from health care reform. Maintain Equal Weight rating and $39 price target.
Eli Lilly estimates lowered at Goldman were cut through 2012 at Goldman Sachs. Company will see lower sales, given health care reform. Sell rating and $34 price target.
estimates, target boosted at FBR Capital Markets. Estimates were raised through 2011. Company is likely seeing better sales trends. Outperform rating and new $30 price target.
numbers boosted at UBS through 2011. Company should benefit from higher memory cap-ex spending. Buy rating and new $52 price target.
added to Conviction Buy list at Goldman Sachs. Decline following the convertible offering has created an attractive buying opportunity. $17.50 price target.
target, estimates cut at Credit Suisse. Price target lowered to $72 from $86 on higher competition. 2010 and 2011 EPS estimates trimmed to $3.13 and $3.58, respectively. Maintain Neutral rating.
estimates, target upped at FBR Capital Markets. Estimates were increased through 2011. Company is seeing lower credit costs and improving capital ratios. Market Perform rating and new $82 price target.
numbers boosted at UBS. Estimates were raised through 2011. Company is finding lots at attractive prices and community growth should accelerate. Neutral rating and new $5.25 price target.
Trina Solar Limited
target raised at Barclays, although estimates are mixed. Price target increased to $27 from $25 as second-half 2010 estimates appear conservative. 2010 EPS estimates cut to $2.49. 2011 EPS estimate raised to $2.04. Equal Weight rating.
target upped at UBS. Shares now seen reaching $82. Company has lagged its peers but should catch up as the economic recovery continues. Buy rating.
estimates lowered at FBR Capital Markets. Estimates were reduced through 2011. Company is seeing softer pricing. Market Perform rating and $25 price target.